Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, both clinically and from
a molecular standpoint. The advent of next-generation sequencing technologies has
provided new opportunities to extensively analyze molecular defects in HCC samples. This
has uncovered major cancer driver genes and associated oncogenic pathways operating in
HCC. More sophisticated analyses of sequencing data have linked specific nucleotide
patterns to external toxic agents and defined so-called 'mutational signatures' in HCC …